Corey Davis

What Analysts Expect For Zynerba's Upcoming Wave Of Data

Cara Therapeutics Top-Line Data Disappoints: 'This Is Why You Do Phase 2'

Has Aerie Pharma Put The 'Binary Boogeyman' To Bed With Roclatan Phase 3 Data?

Cara Therapeutics Top-Line Data Disappoints: 'This Is Why You Do Phase 2'

Has Aerie Pharma Put The 'Binary Boogeyman' To Bed With Roclatan Phase 3 Data?

'Trump Schmump': H.C. Wainwright Raises Zynerba's Target To $30

Zynerba Updates Analysts On Cannabidiol Treatment

'Trump Schmump': H.C. Wainwright Raises Zynerba's Target To $30

Zynerba Updates Analysts On Cannabidiol Treatment

Which Wet AMD Stock Would You Buy Right Now?

What Fovista's Fail Means For OHR Pharma

Corey Davis Recent News

Why Kite Pharma Investors Should Expect Lymphoma Treatment FDA Approval In 2017

Good News And Bad News For Ohr Pharmaceuticals

H.C. Wainwright Is Bullish On Cara Therapeutics Shares

Lipocine Showered With Good News Recently

HC Wainwright's New Buy Rating On Lipocine Suggests 500% Upside

vTv Therapeutics Shares Initiated With Buy Rating, $13 Target

'Grass Is Greener' For Zynerba Pharma: Buy The Stock, Says Canaccord

Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen

UPDATE: Jefferies Downgrades Warner Chilcott on Pending ACT Acquisition

UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals Following Model Assumption Updates

UPDATE: Jefferies Raises PT on Forest Laboratories Following New Board Member Announcement

UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance

UPDATE: Jefferies Raises PT on Salix Pharmaceuticals on Street Estimates Upside

UPDATE: Jefferies Reiterates Hold Rating, Raises PT on Actavis on WCRX Acquisition Announcement

Jefferies & Company Likes Endo Pharmaceuticals (ENDP) Acquisition Plans